Skip to main content
Barbara Losch on Muck Rack

Barbara Losch

As seen in: MarketScreener, Bluefield Daily Telegraph
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Medigene to Present at ESMO Congress 2024

|
By Kanuj Mishra, Justyna Ogonek, Dolores Schendel, Barbara Losch
| Bluefield Daily Telegraph Verified
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters at the ESMO Congress 2024 being held on September 13-17, 2024, in Barcelona, Spain.
Open in Who Shared View Duplicates (136) Issue with article?

Medigene to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy

|
By Andrea Coluccio, Dolores Schendel, Barbara Losch, Dimitri Frishmann
| MarketScreener
Munich - Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 20th Association for Cancer Immunotherapy (CIMT) annual meeting being held on May 3-5, 2023, in Mainz. The data to be presented will focus on Expitope 3.0, an in silico tool to identify immunogenic epitopes as suitable T cell receptor (TCR) target specificities.
Open in Who Shared Issue with article?
See all 2 articles